RESUMEN
Term pregnant patients undergoing preinduction cervical softening were randomized to receive no treatment (controls) or 0.5 mg PGE2-triacetin gel (Prepidil gel) endocervically. Plasma samples containing PGEM collected 4 hrs post-treatment and converted to the stable bicyclo degradation product (bicyclo-PGEM) were assayed by RIA. Positive clinical effect (responders) during 12 hrs after treatment (Bishop score increase greater than or equal to 3, in labor or delivered) were assessed. All evaluations were blind. In nonresponders (n = 35), the means of the bicyclo-PGEM variables (mean, maximum, area under the curve) were all about 18% higher in gel-treated patients (n = 6) than controls (n.s.). In responders (n = 38), the variables were all about 80% higher in gel-treated women (n = 32) than controls (p less than .01). In controls (n = 35), the responders (n = 6) had 50% higher levels than nonresponders (n.s.). In the gel-treated women (n V 38), responders (n = 32) had about 140% higher levels than nonresponders (less than .01). The results suggest that both exogenous and endogenous bicyclo-PGEM were measured. Differences in pairwise comparisons suggest that there may be substantially less exogenous bicyclo-PGEM in the gel nonresponders than in gel responders or substantially more endogenous bicyclo-PGEM in gel responders than in control-responders.
Asunto(s)
Cuello del Útero/efectos de los fármacos , Prostaglandinas E/administración & dosificación , Prostaglandinas E/sangre , Adolescente , Adulto , Ensayos Clínicos como Asunto , Dinoprostona , Femenino , Geles , Humanos , Trabajo de Parto Inducido , Embarazo , Distribución AleatoriaRESUMEN
Since previous literature suggested that estrogen-treated male mice are models for human benign prostatic hypertrophy, a series of studies was designed to examine urine retention and urogenital tract changes in rodents given chronic estradiol-17 beta (E) and dihydrotestosterone (DHT) treatments. In Study 1, intact and castrate male mice received E, DHT or E plus DHT for four weeks via subcutaneous Silastic capsules. Bladder urine volume increased in the groups given E and this effect was not altered by castration, DHT or removal of E capsules two weeks before necropsy. Estrogen treatment also increased mortality. In Study 2, intact male, intact female, adrenalectomized (Adx) male and sham Adx male mice received 16 weeks of steroid treatments. Bladder urine volume increased in all E treated groups regardless of sex or Adx. Hydronephrosis, hydroureter and increased mortality were found in the E treated mice of both sexes. Estrogen induced epithelial changes and edema of the prostate, vas deferens and the utriculus prostaticus. In further studies male rats, hamsters and guinea pigs were given several different dosages of E but no evidence of urine retention or increased mortality was found. Taken together these studies suggest that E-induced urine retention is unique to mice. Although urine retention and hydronephrosis found in the mice were similar to those in humans with BPH, the lesion that results in the urine obstruction is not similar.
Asunto(s)
Dihidrotestosterona/toxicidad , Estradiol/toxicidad , Trastornos Urinarios/inducido químicamente , Sistema Urogenital/efectos de los fármacos , Glándulas Suprarrenales/fisiología , Adrenalectomía , Animales , Castración , Edema/inducido químicamente , Femenino , Enfermedades de los Genitales Masculinos/inducido químicamente , Cobayas , Hidronefrosis/inducido químicamente , Masculino , Ratones , Enfermedades de la Próstata/inducido químicamente , Ratas , Enfermedades Ureterales/inducido químicamenteRESUMEN
U-68,215 [15-Cyclohexyl-9-deoxo-13,14-dihydro-2',9 alpha-methano-4,5,6,16,17,18,19,20-octanor-3-oxa-3,7-(1', 3'-interphenylene)-PGE1] is a stable prostacyclin analog. When given orally to rats, it is cytoprotective for the stomach (ED50: 0.8 micrograms/kg) and the intestine (ED50: 22 micrograms/kg), is gastric antisecretory (ED50: 35 micrograms/kg) and antiulcer (aspirin) (ED50: 5 micrograms/kg). The oral antisecretory ED50 in dogs is 50 micrograms/kg. It has a long duration of gastric cytoprotection: 8-10 hours compared to 3 hours for 16,16-dimethyl PGE2. Unlike most prostaglandins of the E type, it is not diarrheogenic (not enteropooling), it does not induce cellular proliferation of the gastrointestinal mucosa, when given twice a day for eight days, it is not uterotonic (in monkeys), and it does not prevent embryo implantation in hamsters. It inhibits ex vivo platelet aggregation (ED50: 300 micrograms/kg), but does not promote bleeding from cut vessels nor from gastric ulcers. U-68,215 lowers blood pressure at an oral dose corresponding to 1-5 times the antisecretory ED50 in rats and dogs, and to 150 times the cytoprotective ED50 in rats. It may be of therapeutic value in the treatment of conditions where inhibition of gastric acid secretion is desirable, e.g., gastric and duodenal ulcer, and in conditions responding to cytoprotection, e.g., stress ulcers, hemorrhagic gastritis and gastric erosions associated with nonsteroidal antiinflammatory drugs.
Asunto(s)
Alprostadil/análogos & derivados , Antiulcerosos/farmacología , Epoprostenol/análogos & derivados , Intestinos/efectos de los fármacos , Estómago/efectos de los fármacos , Alprostadil/farmacología , Animales , Aspirina/toxicidad , Tiempo de Sangría , Presión Sanguínea/efectos de los fármacos , Sistema Digestivo/citología , Perros , Implantación del Embrión/efectos de los fármacos , Femenino , Jugo Gástrico/efectos de los fármacos , Jugo Gástrico/metabolismo , Indometacina/farmacología , Intestinos/fisiología , Agregación Plaquetaria/efectos de los fármacos , Ratas , Ratas Endogámicas , Estómago/fisiología , Contracción Uterina/efectos de los fármacosAsunto(s)
Alprostadil/análogos & derivados , Fenómenos Fisiológicos del Sistema Digestivo , Epoprostenol/análogos & derivados , Alprostadil/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Sistema Digestivo/efectos de los fármacos , Perros , Femenino , Jugo Gástrico/metabolismo , Macaca mulatta , Masculino , Agregación Plaquetaria/efectos de los fármacos , Embarazo , Ratas , Ratas Endogámicas , Contracción Uterina/efectos de los fármacosAsunto(s)
Bovinos/fisiología , Estro , Ovario/fisiología , Preñez , Útero/fisiología , Animales , Cuerpo Lúteo/anatomía & histología , Cuerpo Lúteo/fisiología , Dinoprost , Electroforesis en Gel de Poliacrilamida , Estradiol/metabolismo , Estrona/sangre , Femenino , Técnicas In Vitro , Peso Molecular , Tamaño de los Órganos , Folículo Ovárico/fisiología , Embarazo , Progesterona/sangre , Prostaglandinas F/metabolismo , Proteínas/metabolismoRESUMEN
Comparisons were made of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 levels in plasma determined by three assay methods. Plasma samples from Rhesus monkeys treated with 200 micrograms/kg 9-deoxo-16,16-dimethyl-9-methylene-PGE2 intravenously were analyzed by radioimmunoassay (RIA) and by high pressure liquid chromatography (HPLC). In a second experiment known amounts of 11 beta-3H-9-deoxo-16,16-dimethyl-9-methylene-PGE2 were added to human plasma at several concentration levels. The samples were analyzed by RIA, HPLC and gas chromatography-mass spectrometry (GC-MS). A limited number of comparisons have been made between RIA and GC-MS analysis of plasma samples from human subjects treated wtih 9-deoxo-16,16-dimethyl-9-methylene-PGE2. The results indicated that the three assay methods generally give comparable estimations of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 content in plasma.
Asunto(s)
16,16-Dimetilprostaglandina E2/sangre , Prostaglandinas E Sintéticas/sangre , 16,16-Dimetilprostaglandina E2/análogos & derivados , Animales , Cromatografía Líquida de Alta Presión , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Cinética , Macaca mulatta , Embarazo , RadioinmunoensayoRESUMEN
A method is described for the estimation of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 by double antibody radioimmunoassay. Plasma samples obtained from animals treated with 9-methylene-16, 16-dimethyl-PGE2, 1-adamantanamic salt were extracted with diethyl ether to recover the prostaglandin. The validation of sample preparation and assay procedure are presented. Rhesus females were treated by several routes of administration and the samples assayed for drug content. Maximum blood levels were probably reached 30 minutes following subcutaneous injection and within 30 seconds of an intravenous injection. Results of the acute intravenous injection indicate an initial half-life of approximately one minute in peripheral circulation. Continuous intravenous infusion at 3 increasing doses of this compound resulted in a stepwise increase in plasma drug concentrations. Vaginal administration of 9-methylene-16, 16-dimethyl-PGE2, 1-adamantanamine salt in suppositories produced a dose dependent increase in plasma drug concentration. Higher plasma drug concentrations were produced when the prostaglandin was delivered in H-15 base suppositories than in E-76 base suppositories.
Asunto(s)
16,16-Dimetilprostaglandina E2/sangre , Prostaglandinas E Sintéticas/sangre , 16,16-Dimetilprostaglandina E2/administración & dosificación , 16,16-Dimetilprostaglandina E2/análogos & derivados , Animales , Femenino , Macaca mulatta , Embarazo , Conejos/inmunología , Radioinmunoensayo/métodos , SupositoriosRESUMEN
A number of PGE analogs have been synthesized in which the C-9 carbonyl group has been replaced by an exo-methylene group. These chemically stable 9-deoxo-9-methylene-PGEs exhibit biological profiles very similar to their less stable PGE relatives. 9-Deoxo-16,16-dimethyl-9-methylene-PGE2 (7) retains the useful uterine-stimulating potency of 16,16-dimethyl-PGE2 but is approximately 300 times less enteropooling in the rat. In preliminary clinical trials, 7 has shown efficacy for pregnancy termination by the oral and vaginal routes of administration, as well as relative freedom from gastrointestinal side effects.
Asunto(s)
16,16-Dimetilprostaglandina E2/síntesis química , Prostaglandinas E Sintéticas/síntesis química , 16,16-Dimetilprostaglandina E2/análogos & derivados , 16,16-Dimetilprostaglandina E2/farmacología , Animales , Bioensayo , Presión Sanguínea/efectos de los fármacos , Cricetinae , Femenino , Jugo Gástrico/efectos de los fármacos , Jugo Gástrico/metabolismo , Motilidad Gastrointestinal/efectos de los fármacos , Gerbillinae , Métodos , Agregación Plaquetaria/efectos de los fármacos , Ratas , Relación Estructura-Actividad , Contracción Uterina/efectos de los fármacosRESUMEN
Intravenous injection of 600 microgram PGE2 or PGI2 significantly increased serum LH and prolactin levels in estradiol treated ovariectomized rats. There was no effect on serum FSH concentration. PGE2 and PGI2 stimulated LH release in a non-dose dependent manner, while prolactin levels were positively correlated with the dose administered following PGI2 treatment. 6-keto-PGF1 alpha at a comparable dose had no effect on pituitary hormone levels. Subcutaneous administration of 1 mg/kg or 60 mg/kg PGI2 for seven days significantly depressed serum LH level both in male and female rats. These doses had no effect on serum FSH or prolactin levels.
Asunto(s)
Epoprostenol/farmacología , Hormonas Adenohipofisarias/sangre , Prostaglandinas/farmacología , Animales , Castración , Relación Dosis-Respuesta a Droga , Femenino , Hormona Folículo Estimulante/sangre , Hormona Luteinizante/sangre , Masculino , Prolactina/sangre , Prostaglandinas E/farmacología , Prostaglandinas F/farmacología , RatasRESUMEN
Adult male rhesus were treated with PGE2, PGF2 alpha or the 13,14-dihydro-15-keto metabolite of PGE2 in a randomized crossover design. Serum concentrations of FSH, LH and testosterone were determined and compared to the respective values in the same uninjected animals. No significant changes were noted in controls or following the metabolite injection. FSH increased gradually for 4 hours after metabolite treatment. In contrast, injection of PGF2 alpha was followed by an abrupt (within 15 minutes) increase in LH and testosterone. FSH increased gradually in 2 of 3 treated animals. Injection of PGE2 was followed by a similar abrupt increase in LH concentration. This was not always associated with a significant increase in testosterone or FSH. These results demonstrate that injections of PGE2 or PGF2 alpha can change serum gonadotropin and testosterone concentrations in male rhesus monkeys, and that the effects of these two prostaglandins are qualitatively different.
Asunto(s)
Hormona Folículo Estimulante/sangre , Hormona Luteinizante/sangre , Prostaglandinas/farmacología , Testosterona/sangre , Animales , Haplorrinos , Macaca mulatta , Masculino , Prostaglandinas E/farmacología , Prostaglandinas F/farmacología , Prostaglandinas F Sintéticas/farmacología , Distribución Aleatoria , Factores de TiempoRESUMEN
The in vivo monkey uterine stimulating potency of 9-deoxy-16,16-dimethyl-9-methylene-PGE2 is similar to that of 16,16-dimethyl-PGE2 and approximately 15 times that of PGE2. Low doses of this compound stimulated uterine contractions when administered vaginally. Pregnancy was terminated prematurely following subcutaneous, intramuscular or vaginal suppository treatment. Estimates of potential for gastrointestinal side effects using the rat enteropooling assay and in vivo monkey effects indicate that diarrhea will be substantially reduced with retention of uterine stimulating potency.
Asunto(s)
Contracción Uterina/efectos de los fármacos , Aborto Inducido , Animales , Fenómenos Químicos , Química , Colon/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Esterificación , Femenino , Jugo Gástrico/metabolismo , Motilidad Gastrointestinal/efectos de los fármacos , Gerbillinae , Haplorrinos , Hidrólisis , Macaca mulatta , Oxidación-Reducción , Embarazo , Prostaglandinas E Sintéticas/administración & dosificación , Prostaglandinas E Sintéticas/farmacología , Tasa de Secreción/efectos de los fármacosRESUMEN
After 4 years of a long-term contraceptive steroid safety study, the incidence and the histologic types of mammary dysplasia produced are shown to be similar in beagles treated with medroxyprogesterone acetate (medroxyprogesterone) or progesterone. Serum insulin, thyroid-stimulating hormone (TSH), triiodothyronine, growth hormone, prolactin, 17 beta-estradiol, progesterone, and cortisol were determined by radioimmunoassay on samples collected after 45 months of treatment. Serum growth hormone and insulin concentrations were elevated in a dose-related manner in both treatment groups. Levels of triiodothyronine, cortisol, and 17 beta-estradiol (medroxyprogesterone only) were lowered. TSH and prolactin concentrations were not changed. Pituitary-gonadal hormone interaction in the pathogenesis of mammary neoplasia of the dog is discussed. Prolonged treatment of beagles with doses of progesterone or medroxyprogesterone 1 to 25 times the human contraceptive dose or luteal phase (dog) levels, respectively, results in a dose-related incidence of mammary nodules.
PIP: The results of a 4-year longterm study of contraceptive safety in mammals are discussed. The animals were treated with either MPA (medroxyprogesterone acetate) or progesterone. Serum insulin, thyroid-stimulating hormone, triiodothyronine, growth hormone, prolactin, 17 beta-estradiol, progesterone, and cortisol were measured by radioimmunoassay on samples collected after 45 months of treatment. No increased incidence of mammary tumors were noted in rats, mice, or monkeys. An increased incidence of mammary dysplasia was, however, noted in dogs. MPA and progesterone produced similar incidence rates, types, and numbers of nodules per animal. The incidence of mammary nodules was dose-related. Microscopic examination of the nodules indicated a similar histology and distribution of change in bitches treated with both substances. Serum prolactin, growth hormone, and insulin responses were similar in both groups. Clinical studies with women being treated with either MPA or progesterone have shown no evidence of treatment-related mammary dysplasia. These studies revealed several significant differences in hormonal response to exogenous progestational compounds between dogs and humans.
Asunto(s)
Adenoma/inducido químicamente , Hormonas/sangre , Glándulas Mamarias Animales/efectos de los fármacos , Medroxiprogesterona/farmacología , Neoplasias/inducido químicamente , Progesterona/farmacología , Animales , Perros , Relación Dosis-Respuesta a Droga , Estradiol/sangre , Femenino , Hormona del Crecimiento/sangre , Hidrocortisona/sangre , Hiperplasia/inducido químicamente , Insulina/sangre , Glándulas Mamarias Animales/patología , Progesterona/sangre , Prolactina/sangre , Tirotropina/sangre , Factores de Tiempo , Triyodotironina/sangreRESUMEN
Pregnant hamsters were administered (SC) prostaglandin or vehicle on the morning of the 4th day of pregnancy. Serum progesterone was significantly depressed (p less than .01) at 0.5, 2, and 6 hours after treatment with 100 microgram PGF2alpha. Serum progesterone levels were unchanged 2 hours and 6 hours after treatment with 100 microgram PGF2beta and 2 hours after treatment with 1 mg PGF2beta. Progesterone levels were depressed to less than 1 ng/ml 6 hours after treatment with 1 mg PGF2beta. The specific uptake of 3H-PGF2alpha in whole hamster corpora lutea was significantly depressed 2 hours and 6 hours following 100 microgram PGF2alpha treatment. A 15% depression in specific uptake occurred 0.5 hour post-treatment. Treatment with 100 microgram PGF2beta resulted in no change. Administration of 1 mg PGF2beta resulted in depressed 3H-PGF2alpha uptake at both 2 and 6 hours post-treatment. Prostacyclin (PGI2) treatment resulted in no change in either 3H-PGF2alpha specific uptake or serum progesterone 2 hours after 100 microgram treatment SC. These parameters were both reduced approximately 30% 6 hours post-treatment. Treatment with 6-keto-PGF1alpha resulted in a complete lack of measurable 3H-PGF2alpha uptake and serum progesterone levels less than 1 ng/ml at both 2 and 6 hours after treatment with 1 mg SC.
Asunto(s)
Cuerpo Lúteo/metabolismo , Epoprostenol/farmacología , Prostaglandinas F/metabolismo , Prostaglandinas/farmacología , Animales , Cricetinae , Depresión Química , Epoprostenol/administración & dosificación , Femenino , Embarazo , Progesterona/sangre , Prostaglandinas F/administración & dosificación , Prostaglandinas F/farmacología , Factores de TiempoRESUMEN
Silicone rubber discs containing 15(S)-15-methyl prostaglandin F2 alpha ester (15-Me-PGF2 alpha) in the matrix were implanted in the left side of the scrotums of Sprague-Dawley rats. The effect of 1% and 2% drug concentration was examined for 10, 20, or 28 days and compared with the effects of Silastic discs containing no prostaglandin. The discs containing prostaglandin reduced mean testicular and accessory gland weights. Histologically the testes and epididymides showed decreased or absent spermatogenic elements and hypertrophy of the interstitial cell masses in comparison with other cells. Implanted prostaglandin significantly depressed serum testosterone, luteinizing hormone, and follicle-stimulating hormone (FSH) concentrations when 15-Me-PGF2 alpha plasma concentrations exceeded 2 ng/ml. Hormone concentrations returned to control values as drug concentrations declined. FSH concentrations significantly exceeded control values 10 and 20 days after implantation, when prostaglandin concentration was nondetectable. The acute suppression of all three hormones suggest that 15-Me-PGF2 alpha either may act directly on the tests to suppress testosterone production or may suppress testosterone production or may suppress gonadotropin secretion, resulting in depressed testosterone output.
Asunto(s)
Genitales Masculinos/efectos de los fármacos , Prostaglandinas F Sintéticas/farmacología , Animales , Peso Corporal/efectos de los fármacos , Implantes de Medicamentos , Epidídimo/patología , Hormona Folículo Estimulante/sangre , Genitales Masculinos/fisiología , Hormona Luteinizante/sangre , Masculino , Tamaño de los Órganos/efectos de los fármacos , Prostaglandinas F Sintéticas/administración & dosificación , Prostaglandinas F Sintéticas/efectos adversos , Ratas , Elastómeros de Silicona , Espermatogénesis/efectos de los fármacos , Testículo/efectos de los fármacos , Testículo/patología , Testículo/fisiología , Testosterona/sangreRESUMEN
Male Spraque-Dawley rats receiving implants of silicone rubber discs containing 1% or 2% 15(S)-15-methyl prostaglandin F2 alpha methyl ester (15-Me-PGF 2 alpha) or no prostaglandin were tested in successive breeding trials for potency and fertility. One week after implantation, discs containing 1% 15-Me-PGF2 alpha reduced potency and fertility, which returned 2 weeks after implantation. Animals receiving implants of the 2% discs were apparently impotent the 1st week following implantation; potency returned before full fertility returned 11 weeks after implantation.
Asunto(s)
Fertilidad/efectos de los fármacos , Prostaglandinas F Sintéticas/farmacología , Animales , Peso Corporal/efectos de los fármacos , Copulación , Implantes de Medicamentos , Femenino , Masculino , Embarazo , Prostaglandinas F Sintéticas/administración & dosificación , Ratas , Elastómeros de SiliconaRESUMEN
The effects of prostaglandin (PG)F2alpha and PGF2alpha, 1-15 lactone were compared in luteal phase, non-pregnant and in early pregnant rhesus monkeys. Animals treated with either PG after pretreatment with human chorionic gonadotropin (hCG) had peripheral plasma progesterone concentrations that were not statistically different from those in animals treated with hCG and vehicle. However, menstrual cycle lengths in monkeys treated with PGF2alpha, 1-15 lactone were significantly (P less than 0.02) shorter than those in vehicle treated animals. In the absence of hCG pretreatment, plasma progesterone concentrations were significantly (P less than 0.008) lower by the second day after the initial treatment with either PGF2alpha or PGF2alpha, 1-15 lactone than in vehicle treated monkeys. Menstrual cycle lengths in monkeys treated with either PG were significantly (P less than 0.04) shorter than those in animals treated with vehicle. There were no changes in plasma progesterone concentrations in early pregnant monkeys treated with PGF2alpha, and pregnancy was not interrupted. In contrast, plasma progesterone declined and pregnancy was terminated in 5 of 6 early pregnant monkeys treated with PGF2alpha, 1-15 lactone. These data indicate that PGF2alpha, 1-15 lactone decreases menstrual cycle lengths in non-pregnant rhesus monkeys. More importantly, PGF2alpha, 1-15 lactone terminates early pregnancy in the monkey at a dose which is less than an ineffective dose of PGF2alpha.
Asunto(s)
Cuerpo Lúteo/efectos de los fármacos , Preñez/efectos de los fármacos , Prostaglandinas F/farmacología , Aborto Inducido , Animales , Gonadotropina Coriónica/farmacología , Femenino , Haplorrinos , Macaca mulatta , Menstruación/efectos de los fármacos , Embarazo , Progesterona/sangre , Prostaglandinas F/administración & dosificación , Factores de Tiempo , Contracción Uterina/efectos de los fármacosRESUMEN
Preliminary studies indicate the presence of PGF2alpha specific binding sites in membrane fractions prepared from equine corpora lutea. The equilibrium binding data indicate an apparent dissociation constant of 3.2 X 10(-9)M and the concentration of binding sites of -0.1 pmoles/mg membrane protein. Competition of several natural prostaglandins for equine luteal PGF2alpha specific binding sites indicates specificity for the 9alpha-hydroxyl moiety and the 5,6-cis doublebond. Significant increases in relative binding affinities were demonstrated for PGF2alpha analogs with a phenyl ring introduced at carbons 16 or 17. Specific PGF2alpha binding was demonstrated in corpora lutea collected at known stages of the estrous cycle. There was no pattern in these values based on the stage of the cycle. While specific 3H-PGE1 binding could be demonstrated, no high affinity sites could be quantitated. 3H-PGE1 binding appeared unaffected by changes in temperature or time of incubation, whereas PGF2alpha specific binding was significantly modified by both these factors.
Asunto(s)
Cuerpo Lúteo/metabolismo , Prostaglandinas F/metabolismo , Animales , Sitios de Unión , Unión Competitiva , Membrana Celular/metabolismo , Estro , Femenino , Caballos , Embarazo , TemperaturaRESUMEN
The relative binding affinities for both the prostaglandin (PG)E1 and PGF2alpha specific bovine luteal binding sites were determined for five PGE and fourteen PGF derivatives and analogs. Relative binding affinity was determined in vitro using membranes prepared from bovine corpora luteal (CL) obtained from the slaughterhouse. The parent structure of the analog was a dominant feature in determining the affinity for the respective PG binding site. Luteolysis was determined in cattle following intramuscular injection of various doses of prostaglandin once between days 6 and 14 after estrus and measuring CL regression by ovarian palpation per rectum, interval between injection and return to estrus and duration of the subsequent estrous cycle. A dose which was luteolytic was established for each of eight PGF-type compounds, and a dose which was not luteolytic was also established. There appeared to be limited association between the relative affinity for the PGF2alpha specific site in vitro and the estimated luteolytic dose range of these PGF analogs when tested in cattle. Differences in in vivo luteolytic potency for the compounds tested could not be explained by differences in binding affinity. Differences in metabolism and absorption may also be important in the determination of in vivo potency.
Asunto(s)
Cuerpo Lúteo/metabolismo , Prostaglandinas E/metabolismo , Prostaglandinas F/metabolismo , Receptores de Superficie Celular , Receptores de Prostaglandina , Animales , Bovinos , Membrana Celular/metabolismo , Cuerpo Lúteo/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Estro , Femenino , Embarazo , Prostaglandinas E/farmacología , Prostaglandinas F/biosíntesis , Prostaglandinas F/farmacología , Unión Proteica/efectos de los fármacos , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Prostaglandina/efectos de los fármacosAsunto(s)
Ovario/efectos de los fármacos , Prostaglandinas/farmacología , Útero/efectos de los fármacos , Aborto Inducido , Animales , Sitios de Unión , Cuerpo Lúteo/efectos de los fármacos , Trompas Uterinas/efectos de los fármacos , Femenino , Contracción Muscular/efectos de los fármacos , Ovario/irrigación sanguínea , Prostaglandinas/metabolismo , Prostaglandinas E/metabolismo , Prostaglandinas F/metabolismo , Flujo Sanguíneo Regional/efectos de los fármacos , Útero/irrigación sanguíneaRESUMEN
Myometrial low speed supernatant prepared from non-pregnant rhesus uteri was incubated with 3H-Prostaglandin (PG)E1 with or without addition of unlabelled prostaglandins. The uptake of 3H-PGE1 was inhibited in a dose dependent fashion by PGE2greater thanPGE1greater thanPGA1greater thanpgf2alpha=PGA1greater thanPGB1=PGB2greater than or equal toPGD2. PGE1 metabolites inhibited 3H-PGE1 binding in the following order: 13, 14-dihydro-PGE1greater than13,14-dihydro-15-keto-PGE1=15-keto-PGE1. The specific binding of 3H-PGE1 and 3H-PGF2alpha was similarly affected by the temperature and time of incubation. Equilibrium binding constants determined using rhesus uteri obtained during the luteal phase of the menstrual cycle indicate the presence of high affinity PGE1 binding sites with an average (n=3) apparent dissociation constant of 2.2 X 10(-9)M and a lower affinity PGE1 binding site with a Kd approximately equal to 1 X 10(-8)M. No high affinity - low capacity 3H-PGF2alpha sites could be demonstrated. Relative uterine stimulating potencies of some natural prostaglandins and prostaglandin analogs tested after acute intravenous administration in mid-pregnant rhesus monkeys corresponded with the PGE1 binding inhibition of the respective compound. The uterine stimulating potencies of the prostaglandin analogs tested were: (15S)-15-methyl-PGE2=16,16-dimethyl-PGE2greater than17-phenyl-18,19,20-trinor-PGE2greater than16 phenoxy-17,18,19,20-tetranor-PGF2alpha=PGE2=PGE1=(15S)-15-methyl-PGF2alpha greater than PGF2alpha.